Bill of Health

NOVEMBER 15, 2023

DEA has done little to reduce the appearance of agency capture by the Opioid Treatment Program (OTP) industry, while FDA was years behind the evidence in approving over-the-counter naloxone.

Governance 173

Governance Public Health Telemedicine COVID-19 173

Healthcare Law Today

FEBRUARY 1, 2022

Improves clinical trials by requiring the Food and Drug Administration (FDA) to issue guidance on the use of digital health technologies in clinical trials; decentralized clinical trials; and other innovative designs to support development of new drugs. Senators Murray and Burr expect the legislation to progress this year.

COVID-19 98

COVID-19 FDA Public Health Health Services Administration 98

HIT Consultant

FEBRUARY 23, 2023

Opioid Use Disorder Treatment to Federal Bureau of Prisons The collaboration will enable patients to access Bicycle Health’s evidence-based, life-saving clinical care model delivering virtual Medication for Opioid Use Disorder (MOUD) services to individuals living in the FBOP’s Residential Reentry Centers (RRC).

Health Services Administration 52

Health Services Administration FDA 52

The Digital Health Corner

NOVEMBER 28, 2016

The Substance Abuse and Mental Health Services Administration recently released a free mobile app for clinicians called MATx. The Agency for Healthcare Research and Quality is launching a three-year $19M initiative focusing on mobile apps and telehealth aids for rural physicians in efforts to treat opioid addiction.

Public Health 68

Public Health Health Services Administration Patient Advocacy Governance 68

Healthcare Law Today

NOVEMBER 9, 2022

Prior to the federal COVID-19 Public Health Emergency (PHE), to initiate treatment with buprenorphine at an OTP, a practitioner needed to perform a complete in-person physical evaluation. The covered benefit includes MAT for patients with OUD, a leading treatment modality that combines prescribing FDA-approved medication (e.g.,

Medicare 52

Medicare Medicare COVID-19 Telemedicine 52

Health Law Advisor

MARCH 7, 2023

Should the final rules limit the issuance of prescriptions of controlled medications to the FDA-approved indications contained in the FDA-approved labeling for those medications? DEA has specifically requested feedback on whether it should limit telemedicine prescribing to only the drug’s FDA-approved indications. 21 U.S.C. §

Telemedicine 52

Telemedicine COVID-19 FDA Compliance 52

HIPAA Journal

DECEMBER 22, 2022

Funding for the Centers for Medicare and Medicaid Services will increase by $100 million, the National Institutes of Health will receive an additional $2.5 Those requirements will take effect 90 days after the bill is enacted.

FDA 114

FDA COVID-19 Governance Medicaid 114